Bayesian Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bayesian Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-28,000	Closed	-$370K	–	935
2024 Q4	$370K	Buy	+28,000	New	+$479K	0.05%	442
2024 Q1	–	Sell	-15,116	Closed	-$327K	–	1093
2023 Q4	$327K	Buy	+15,116	New	+$232K	0.03%	478
2023 Q3	–	Sell	-17,669	Closed	-$370K	–	981
2023 Q2	$370K	Sell	17,669 -995	-5%	-$20.7K	0.04%	485
2023 Q1	$394K	Sell	18,664 -1,700	-8%	-$42.3K	0.05%	452
2022 Q4	$518K	Buy	20,364 +9,487	+87%	+$221K	0.08%	353
2022 Q3	$261K	Buy	+10,877	New	+$244K	0.05%	457

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bayesian Capital Management's SNDX Position: Q1 2025 in Review

Bayesian Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2025, closing a stake of 28,000 shares — an estimated $370K sold.

Bayesian Capital Management first reported a position in SNDX in Q3 2022 and held it in 6 quarters. The position peaked at $518K in Q4 2022. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

Bayesian Capital Management reported no remaining Syndax Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 28,000 Syndax Pharmaceuticals shares in Q1 2025, an estimated $370K.
Bayesian Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2022 and held it in 6 quarters.
Bayesian Capital Management's Syndax Pharmaceuticals position peaked at $518K in Q4 2022.
218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.